Sirichai Pasadhika, MD
Retina Specialist · Portland, ORNPI 1962622951
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Amgen at 52.9% of the total. Reporting peaked in 2020 at $4,693 and has fallen 96.4% since, to $170 in 2024.
Across 17 payments — averaging $333.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Eyepoint US, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$437
- Genentech USA, Inc.$280
- Novartis$108
- Bausch & Lomb Americas Inc.$102
- plus $58 from 2 others
Across 9 payments — averaging $4055.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$22K
- Eyepoint US, Inc.$14K
What the payments were for
- Consulting fees$1,62029%
- Speaking & faculty fees$3,00053%
- Food & beverage$99618%
- Education$200%
- Gifts$391%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 1 | $3,000 |
| Eyepoint US, Inc. | 3 | $1,689 |
| Regeneron Healthcare Solutions, Inc. | 5 | $437 |
| Genentech USA, Inc. | 2 | $280 |
| Novartis | 2 | $108 |
| Bausch & Lomb Americas Inc. | 1 | $102 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Alcon | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,675 in reported general payments places this provider in the 80th percentile of 36 retina specialist providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 167 | $8,219 |
| Valganciclovir Hcl | 31 | $6,615 |
| Difluprednate | 47 | $5,166 |
| ValacyclovirValacyclovir Hcl | 49 | $5,057 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $3,963 |
| Bromfenac Sodium | 16 | $2,505 |
| Mycophenolate Mofetil | 23 | $2,380 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 91 | $1,647 |
| Azathioprine | 25 | $1,399 |
| Brimonidine Tartrate | 109 | $935 |
| Latanoprost | 80 | $902 |
| Dorzolamide Hcl | 44 | $754 |
| Ketorolac Tromethamine | 33 | $753 |
| Ofloxacin | 45 | $527 |
| Timolol Maleate | 41 | $399 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Portland
- Brian Chan KaiPortland$155K
- Brandon LujanPortland$33K
- Andreas LauerPortland$17K
- David WilsonPortland$5K
- Harpal SandhuPortland$3K
- Aristomenis ThanosPortland$3K
- Michael LeePortland$3K
- Paul TlucekPortland$2K
- Kavita BhavsarPortland$2K
- Apurva PatelPortland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.